<?xml version='1.0' encoding='utf-8'?>
<document id="25542268"><sentence text="Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation." /><sentence text="Patients undergoing hematopoietic stem cell transplantation (HSCT) are at risk of developing potential drug-drug interactions (PDDIs)" /><sentence text=" The aim of this study was to assess the prevalence of PDDIs that occur in HSCT patients on the day of hematopoietic stem cell infusion" /><sentence text=" We performed a cross-sectional study based on the evaluation of prescriptions to HSCT patients on the day of infusion (day 0)" /><sentence text=" The PDDIs were analyzed using the DRUG-REAX(Â®) system and classified according to the severity level, available scientific evidence, time of onset, and potential clinical impact" /><sentence text=" Forty patients undergoing HSCT were included in this study; 33 patients (82" /><sentence text="5%) were exposed to at least one major and one contraindicated PDDI in a concomitant manner" /><sentence text=" All patients exposed to PDDIs had an increased risk of cardiotoxicity" /><sentence text=" Most cases of PDDIs were classified as being of major severity (80" /><sentence text="9%), with time of onset not specified (61" /><sentence text="9%), and with good or excellent scientific evidence (52" /><sentence text="4%)" /><sentence text=" HSCT patients have a high prevalence of clinically significant PDDIs" /><sentence text=" The management of PDDIs requires an approach that includes biochemical tests, installation of cardiac monitors, periodic electrocardiograms, implementation of electronic prescriptions with a PDDI alert system, and availability of the PDDI databases" /><sentence text="" /></document>